ArticleJournal of maxillofacial and oral surgery2022
Ameloblastoma: Retrospective Study and Analysis of 102 Cases Over 10 Years, Single Centre, Institutional Experience.
Article in Journal of maxillofacial and oral surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Implant-supported prosthetic rehabilitation after Ameloblastomas treatment: a systematic review.BMC oral health · 2023Pooled it
- Human Amniotic Mesenchymal Stromal Cells Promote Bone Regeneration via Regulating Ameloblastoma-Derived-Bone Marrow Mesenchymal Cells Crosstalk and Autophagy in Ameloblastoma Microenvironment.Tissue engineering and regenerative medicine · 2026Article
- Clinicopathological and Immunohistochemical Risk Predictors for Ameloblastoma Recurrence.Head and neck pathology · 2025Observational
- Factors Associated with Recurrence of Ameloblastoma: A Scoping Review.Head and neck pathology · 2024Article
- Segmental resection vs. partial resection on treating solid multicystic ameloblastomas of the jaws - recurrence rates: A systematic review and meta-analysis.Journal of clinical and experimental dentistry · 2023Article
- An ameloblastoma mimicking an odontogenic cyst in the right posterior mandible.Journal of dental sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of the study was to analyse the long-term results of ameloblastoma, which was treated at our centre. Study Design: We carried out a retrospective study of 10 years of clinical records from 2007 to 2016 with 102 consecutive cases of ameloblastoma. Data of all patients were collected and analysed with follow-up to 9 years. Results: The data analysis revealed male (59.8%) predominance over female (40.2%) with a mean age of 30.35 ± 15.12 years was observed. We have observed a mandibular (93.1%) than maxilla (6.9%) with left side predominance (54.9%). Anatomically, in the mandible, most of the cases were located in ramus (27.5%). On radiographic analysis, multilocular lesion (66.4%) was observed in association with involvement of impacted mandibular third molar teeth. On histopathological examination, conventional type (63.8%) was most commonly noted. The most frequently performed procedure was segmental mandibulectomy (30.4%). Reconstruction was done in most of the cases by recon plate (41.2%). The recurrence rate was seen at about 20.6%. Conclusion: Ameloblastoma has got mandibular posterior region with male predominance. Follicular ameloblastoma was the most common histological type found. So, Radical approach for adult patients wherein younger and growing patients conservative approach could be a justified as a treatment of choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.